February 7th, 2009
February 7th, 2009
In recognition of National Wear Red Day, an event was held on our corporate campus to raise awareness of the #1 killer of women — heart disease — and to encourage employees to have a quick health check. Rather than scribbling down a few words to describe it, Rob Halper and I thought we’d talk to a few of our friends and colleagues and capture it on video:
BTW, Johnson & Johnson is a national sponsor of The Heart Truth‘s Red Dress Collection Fashion Show. The Heart Truth is a campaign sponsored by the National Heart, Lung, and Blood Institute.
February 6th, 2009
Earlier this week, Mark Senak of Fleishman-Hillard and of Eye On FDA fame uploaded a podcast to his blog of an interview with yours truly and Rob Halper, who is responsible for the Johnson & Johnson health channel on YouTube.
In this interview, we both talked a bit about the steps we took at Johnson & Johnson to get involved with social media. We covered how our colleague Margaret Gurowitz blazed the initial trail through the legal and regulatory jungle with her Kilmer House blog, how I then created JNJBTW and how Rob took what we learned to help establish the Johnson & Johnson health channel on YouTube . Given the podcast is only about 10 minutes long — and given I tend to talk WAY too much — Rob and I only briefly touch on what all of this involved, but we did cover a few key points that other companies could keep in mind:
1) In a highly regulated industry, work closely with your legal and regulatory groups to understand their concerns about the risks associated with different social media projects.
2) Once you understand their concerns, develop an approach that minimizes or mitigates those risks.
3) Start small — by doing so you can dispel some of the perceived risks and gain experience that can be applied to more complex endeavors.
February 4th, 2009
By Conrad Person, Director, Corporate Contributions, Johnson & Johnson
It is a pretty place, well off the road with clouds of blue-blossomed jacaranda trees and flowers tucked into every corner. The buildings are concrete and corrugated steel, frugal in design, but built to last. The luckiest dog in Kenya approaches, sniffs and with a wag of his tail pronounces me no threat.
The Nayumbani Children of God Home in Nairobi exists because a Jesuit priest from America felt he was called to ask what Kenya was going to do about its HIV positive orphans. Father Angelo D’Agostino did not like the answer, so he applied his considerable powers of persuasion to any number of politicians, doctors and just plain folks until he was given a tract of land and an enthusiastic Godspeed.
This was in the bad old days when the diagnosis of HIV stripped people of everything. The virus picked away at their resistance, changed parents from protectors and caregivers into reed thin mockeries of themselves. But stigma was the cruelest thief. It took their jobs, their friends, their very place in society.
How much more remarkable was Father D’Ag in that he did not see his orphanage as heaven’s waiting room.
February 3rd, 2009
As people continue to assess the current economic situation, the need for innovative solutions is an oft-discussed topic.
Dr. Paul Stoffels, who is chairman of Pharmaceutical Research and Development at Johnson & Johnson, has been rather outspoken on this very subject – as discussed last week in the WSJ Health Blog and more recently in an opinion article in the Boston Globe.
Detailing his vision of the future based on innovation, Paul explained in the Globe piece that:
As a physician, a pharmaceutical research and development business leader, and a global citizen, I see one major road to economic recovery and that is through innovation.
In addition to calling for collaborative innovation in the post-crisis world, aimed at economic recovery, Paul also explained the need for collaborative innovation in the pharmaceutical industry.
Through open innovation, he believes there will be an increase in intellectual entrepreneurship and novel collaborations across institutions and geographies. As he explained, this joint effort will then fuel the discovery of solutions to some of the world’s most critical healthcare challenges and meet unmet medical needs for patients worldwide.
In the Boston Globe editorial, Paul goes on to describe some examples of open innovation within the Johnson & Johnson familiy of companies:
At Johnson & Johnson, we are shifting our innovation ecosystem toward an open innovation model, tapping into both institutes of scientific excellence and our own research and development centers across the world.
January 27th, 2009
January 27th, 2009
By Scott Ratzan, MD, Vice President, Global Health, Government Affairs, Johnson & Johnson
As many of us here in the US brace for several days of bitter cold, which carries with it the risk of illness and injury, I’m reminded of the important role that global health research plays in improving people’s lives.
Whether it is the over-the-counter treatments taken to help alleviate the symptoms of the common cold, the prescription antibiotics taken to knock out a bacterial infection, or the hip and knee replacements that help restore mobility, most of us have no doubt benefited in some way from the byproducts of medical research.
Yet all too often we forget that people in some of the world’s poorest nations aren’t so fortunate and lack the information and options needed to treat some of the debilitating diseases that affect them. But now I hope to do something more to help raise awareness of this situation.
I recently had the honor of being named one of twenty five “ambassadors” selected by Research!America’s Paul G. Rogers Society for Global Health Research to advocate for greater US investment in global health research. As part of effort, I’ll be joining some of our nation’s foremost health research experts in an effort to encourage a more robust national discussion on the value and importance of global health research.
January 12th, 2009
January 6th, 2009
Yesterday, I learned that Pharmalot, one of the blogs I read every day, is going to close shop. The news comes as the brains behind the blog, Ed Silverman, decided to leave his employer, the Newark Star Ledger, and join Elsevier. As the WSJ Health Blog points out, the Ledger, like many daily papers that are facing challenging times, cut 40% of its staff — and Ed decided to take a package.
I’m really going to miss Pharmalot. As I said, I read it every day — but not just for the posts. It’s the comments that I often find most intriguing. Through Pharmalot, Ed tapped into a community of people who are interested about the business of healthcare — from people who may work for one of the companies that make New Jersey the “medicine chest for the nation” — to people who are simply interested in health. In his final post (which is well worth reading) Ed sums this up well:
And what a community. Some of you angrily attacked pharma. Some of you vociferously defended it. So often, there were many different perspectives on any number of topics. Whatever the point of view, the discussions were extremely informative.
December 22nd, 2008
Earlier today, our Janssen L.P. company provided some perspective on a series of articles that have appeared about their relationship with Dr. Joseph Biederman and Massachusetts General Hospital to Janssen’s corporate website. I thought those who are following this matter would find this of interest.